Summary Prostaglandins of the A series (PGAs) Daily treatment with di-M-PGA2 strongly suppressed NK activity in normal mice but had no significant effect in tumour-bearing immunodepressed mice. PGA treatment of effector or target cells in vitro, or PGA added during the NK assay, had no effect on NK activity. We suggest that the chemotherapeutic effect of PGA is due to a direct action on tumour cell replication rather than to a stimulation of the host NK activity.
Since the first observation that tumour tissue produces much larger amounts of prostaglandins (PGs) than normal tissue , there has been a great deal of research aimed at evaluating the relationships between PGs and tumour cell growth and functions. PGs are known to be involved in regulating cell proliferation and differentiation in a large number of systems in vitro and in vivo. However, their action varies with the molecular structure, the dose and the animal model (for reviews see Jaffe & Santoro, 1977; Honn et al., 1981; Garaci et al., 1987b) . In particular prostaglandin A, E and D compounds (PGAs, PGEs and PGDs respectively) inhibit the growth and/or stimulate the differentiation of several animal and human leukaemic cell lines, among which are WEHI-3B-D-mouse myelomonocytic leukaemia (Moore, 1982) , L-1210 mouse leukaemia (Narumiya & Fukushima, 1985) , Ml mouse myeloid leukaemia (Honma et al., 1980) , HL-60 human promyelocytic leukaemia (Breitman, 1987) , U-937 human lymphoma (Olsson et al., 1982) and K562 human erythroleukaemia (Santoro et al., 1986 (Santoro et al., , 1989 Santoro, 1987) . PGs also have been shown to play a role in controlling the growth and differentiation of normal erythroid precursors, and PGE and PGA compounds were found to stimulate erythropoiesis in vivo and in vitro (for a review see Santoro & Jaffe, 1990) .
For several years we have studied the role of prostaglandins in the modulation of growth and differentiation of the virus-induced murine Friend erythroleukaemia cells (FLC) . These cells grow indefinitely in suspension culture and can be induced to differentiate in vitro from a pro-erythroblast-like to a normoblast-like stage that produces haemoglobin upon stimulation with dimethylsulfoxide (DMSO) and several other agents (Santoro & Jaffe, 1982) .
FLC inoculated intravenously (i.v.) into DBA/2 mice produces a malignant disease characterised by leukaemic cell infiltration of marrow, lymph nodes, liver and spleen (Preisler et al., 1976) . After subcutaneous (s.c.) inoculation, they produce s.c. tumours similar to myeloblastomas, which cause the death of the animals within 3-7 weeks. Differentiating FLC, i.e. FLC pretreated in vitro with DMSO, produce smaller tumours and permit longer mouse survival than do undifferentiated cells (Friend et al., 1971; Preisler et al., 1976) .
We have previously produced evidence that endogenous PGE is involved in regulating FLC differentiation and proliferation in vitro (Santoro et al., 1979a) , and that a PGE2 analogue (16, 16-dimethyl-PGE2-methyl ester; di-M-PGE2) inhibited FLC tumour growth in vivo and increased the survival of mice injected s.c. with FLC (Santoro & Jaffe, 1979) . We have also shown that PGA compounds are the most effective PGs for inhibiting FLC proliferation in vitro, and are the only PGs studied that can stimulate differentiation in the absence of other inducers (Santoro et al., 1979b) .
The purpose of the present study was to determine whether PGA-treatment could affect FLC tumorigenicity or FLC proliferation in vivo. Since PGs can affect the immune response (Goodwin & Webb, 1980) , we also examined the effect of PGA on the activation of natural killer cells in vitro and in vivo. While the natural PGA compounds were used in vitro, for in vivo studies we used a long-acting synthetic analogue of PGA2, 16, , which has the same activity as PGA, on FLC growth and differentiation in vitro (Santoro & Jaffe, 1982) , and in which the presence of the two methyl groups in position 16 blocks degradation via 15-hydroxy-dehydrogenase (Pike & Bundy, 1982 5'Cr labelling of cells and NK assay NK activity was detected by using the NK-highly sensitive YAC-I cell line. YAC-l thymoma was maintained in CCM. Labelling of cells and measurement of NK activity were performed as previously described (Marini et al., 1985) . For di-M-PGA2 treatment of target cells, YAC-1 cells were suspended in 8 ml of CCM (106 cells ml-') and then incubated overnight at 37°C in the presence of 2 igml-l di-M-PGA2. Tumour cells were then washed three times with phosphate buffer solution, pH 7.2 (PBS), counted, resuspended in CCM and used in assays. In other experiments di-M-PGA2 (2 Ag ml ') was added to the medium during the test. As described in the text, in one experiment K562 human erythroleukaemic cells were used as targets and peripheral blood lymphocytes from a healthy human donor were used as attacker cells.
To prepare labelled target cells for cytotoxicity assays, YAC-1 cells were removed from continuous culture, centrifuged (250 g for 10 min) and resuspended in 0.1 ml of FBS.
After addition of 100 jlCi sodium chromate (5'Cr) (Amer- sham International, Amersham, UK), the cells were incubated for 1 h at 37°C in a 5% CO2 humidified atmosphere. Labelled cells were washed three times with RPMI 1640 containing 10 mM HEPES, 2% heat-inactivated FBS and 50 jig ml-' gentamicin, and then resuspended in another aliquot of the same medium supplemented with 10% FBS (Chromium Release Assay medium, CRA). The viable cell number was then adjusted to 105 ml-'. Assays were performed in U-shaped 96-well microtitre plates (Greiner C.A. and Sohne, Nurtingen, FRG). After serial two-fold dilution starting at 107 cells ml-', effector spleen cells were plated in 0.1 ml CRA and labelled target cells in 0.1 ml were added.
Plates were then incubated for 4 h at 37°C in a 5% CO2 incubator, centrifuged (800 g for 10 min) and radioactivity in 0.1 ml of supernatant was measured in a Packard y scintillation counter. All assays were performed in quadruplicate and four effector: target (E:T) ratios were employed. The (Figure la) . PGA,-pretreatment of FLC had no significant effect on mouse survival (Figure lb) or on tumour growth (at day 16 post-injection the tumour diameters were: 18.4 ± 3.5 mm in controls and 14.9 ± 3.9 mm in PGA,-pretreated mice, P <0.1).
Effect of di-M-PGA2 treatment in vivo In two separate experiments untreated, undifferentiated FLC derived from a logarithmically growing population were injected in DBA/2 mice as previously described. After 2-3 h the mice were randomised (10-15 mice per group) and injected i.p. with 1001il of sterile 154mM NaCl containing 10 ljg di-M-PGA2. Injections were repeated daily up to day 21 p.i. (protocol A), or to day 16 (protocol B). Control mice were treated with the same amount of diluent. Tumour appearance was slightly delayed by di-M-PGA2 treatment (6 days p.i. visible tumours were present in 75% of PG-treated as compared to 92% of control mice in protocol A, and 80% as compared to 100% of control in protocol B; P<0.01). After appearance, the tumours grew rapidly in a rather uniform spherical shape, and their diameters were measured daily (Figure 2a, b) . In protocol B at day 16 p.i. the mice were killed and tumours were removed and weighed. Results are illustrated in Table I . Di-M-PGA2 treatment reduced the rate of tumour growth measured both as tumour diameter (P < 0.05) and tumour weight (P < 0.02). PG-treatment, even though it caused diarrhoea in the first hour after injection, did not alter the weight of tumour-bearing (Table I) Di-M-PGA2 treatment increased mouse survival. Figure 3 shows the survival curves of animals that had been injected with di-M-PGA2 (10 jig per injection) once daily for 21 days (group I, Figure 3a) , or twice daily for 13 days, followed by The rate of tumour appearance. In mice that received PGA,-treated FLC, the appearance of tumours was delayed (P<0.01). b, Mouse survival. No difference in per cent survival was observed between the two groups, up to 100 days post-injection. one injection per day for a further 10 days (group II, Figure  3b ). Median survival was increased by 15% in group I (P<0.01) and by 35% in group II (P<0.005). However, while it significantly increased mice median survival, treatment with the twice daily dose of di-M-PGA2 had no effect on tumour appearance (day 6 p.i.: controls = 54%; di-M-PGA2 = 46%; P<0.5), possibly due to an effect on the immune system in the first days after tumour inoculation, when the animals are not yet immunodepressed by tumour growth.
Measurement of NK activity in normal and tumour-bearing mice after di-M-PGA2 treatment In order to evaluate whether the anti-tumour effect of di-M-PGA2 is mediated by a modulation of NK activity, 36 fiveweek-old mice were inoculated s.c. with 5 x 105 Friend erythroleukaemic cells, in two separate experiments, and treated with di-M-PGA2 (10 ig per day per mouse) or control diluent for the following 15 days; 14 animals not inoculated with FLC were randomly divided into two groups and treated identically. Spleens from control and tumour-bearing Figure 4 shows that at 15 days p.i. the NK activity was 45% less in animals inoculated with FLC compared to normal controls (P<0.02). Di-M-PGA2 treatment strongly suppressed (52%) NK activity in normal mice but it did not further decrease the depressed NK activity in tumour-bearing mice ( Figure  4b ). In order to investigate whether the immune-modulating action of di-M-PGA2 could be mimicked in vitro, the effect of di-M-PGA2 was studied on NK activity either by separately treating effector and target cells or by adding di-M-PGA2 directly during NK assay. Spleen cells (106ml-' in 10ml The last day of treatment mice were killed, the spleens were collected and NK activity was measured in both normal (a) and tumour-bearing (b) animals either untreated (0 0) or treated with di-M-PGA2 (@ 0). Four mice were tested for each group and each mouse was tested individually in quadruplicate. NK activity was lower in di-M-PGA2-treated normal mice (P <0.02) but the analogue had little or no effect in immunodepressed tumour-bearing animals.
Finally, addition of di-M-PGA2 (2 jig ml-') or ethanol control during the NK test (with YAC-1 cells) did not cause any change in the cytotoxicity (controls 26.2 ± 0.9%; ethanol controls 27.8 ± 1.3%; di-M-PGA2 29.1 ± 1.2% cytotoxicity; E:T ratio 100:1).
CCM) from normal animals were treated in vitro for 4 h with 2 jig ml1' di-M-PGA2 or control diluent and thereafter used as attacker cells in the NK assay. This short-term in vitro di-M-PGA2 treatment did not modulate NK activity (25.4 ± 0.9% cytotoxicity in controls versus 24.0 ± 0.3% cytotoxicity in PG-treated spleen cells, E:T ratio 100:1). NK activity of splenocytes tested after 20h of incubation with di-M-PGA2 or control solutions was too low to be measured.
Further experiments have been performed which demonstrate that di-M-PGA2 activity was not due to a modulation of NK susceptibility in target tumour cells. YAC-1 cells or the human erythroleukaemia K562 cells (106 cells ml-') were treated overnight with di-M-PGA2 (2 jig ml-') and used as targets for NK assay, after 5'Cr-labelling. Di-M-PGA2-treated target cells showed similar NK susceptibility compared to control cells (for YAC-1 target cells: controls 34.5 ± 1.7%, di-M-PGA2 34.8 ± 1.4% cytotoxicity; for K562 target cells: controls 77.7 ± 0.8%, di-M-PGA2 75.6 ± 1.0% cytotoxicity; E:T ratio 100:1).
Discussion
The results described in this paper show that systemic administration of a long-acting analogue of PGA2, di-M-PGA2, inhibited FLC tumour growth in vivo. All the variables measured, i.e. tumour time of appearance, diameter and weight, were reduced by PG-treatment while the length of survival of PG-treated mice was increased. These effects were similar to those obtained with di-M-PGE2 in vivo (Santoro & Jaffe, 1979) Eisenbarth and Lebovitz (1974) showed inhibition of chondrosarcoma growth by PGAI.
PGA compounds also inhibit murine and human melanoma growth and human breast cancer cells in a concentrationdependent manner in vitro (Bregman & Meyskens, 1983; Shahabi et al., 1987) . In in vivo studies Stein-Werblowsky (1974) showed that PGA2 inhibited tumour-take and growth in Wistar rats injected with benzopyrene-induced tumour cells. Subcutaneous injections of PGA, (40mgkg-'day-') suppressed by 20% the growth of established human melanoma tumours in athymic nude mice, while higher doses (100-200 mg kg-' day-') produced an 80% reduction in tumour size (Bregman et al., 1986) . Reversible toxicity (diarrhoea and skin inflammation) was associated with these higher doses.
We have previously shown that PGA, (10 yg day-') substantially inhibited the rate of tumour growth in C57B1 mice inoculated with B16 melanoma, in association with a stimulation of the humoral and the cellular immune response (Favalli et al., 1980) . The role of prostaglandins in the regulation of immune response has been studied in detail (for reviews see Goodwin & Webb, 1980; Garaci et al., 1987b ). Voth et al. (1986 found that injection of two cyclooxygenase inhibitors, indomethacin and aspirin, into the peritoneal cavity of mice markedly induced natural killer cell activity. PGE2 injection counteracted the indomethacininduced activation of NK cells. On the other hand, the type of effect of PGA compounds on NK activity in vitro (Bankhurst, 1982) was concentration-dependent: doses of 10-6 M were suppressive and 10-'°M caused slight stimulation.
We therefore studied the effect of di-M-PGA2 treatment on the activity of NK cells, which are considered to play an important role in immunosurveillance against tumour cells (Hanna & Burton, 1981) , in normal and FLC tumourbearing DBA mice. NK activity was profoundly suppressed in tumour bearing mice as compared to control animals. Di-M-PGA2, similarly to PGE2 (Garaci et al., 1987a) , inhibited by 50% the NK activity of normal mice, but had no significant effect on the NK activity of immunodepressed tumour-bearing animals.
Pretreatment of effector cells or addition of di-M-PGA2 at concentrations as high as 4 jLg ml1i during the NK assay had no effect on NK activity, thus excluding a direct action of di-M-PGA2 in this system. The possibility that PGA might modulate the NK susceptibility of tumour target cells (e.g. by alterating membrane fluidity) has also been tested. In vitro pre-treatment of YAC-1 or K562 target cells with PGA, did not change NK susceptibility.
The possibility that di-M-PGA2 exerts its chemotherapeutic properties by modulating other functions of the immune system cannot be excluded, but these data, together with the observation that PGA compounds inhibit FLC proliferation in vitro (Santoro et al., 1979b) , suggest that di-M-PGA2 could be acting directly on tumour cell replication. PGA antiproliferative activity has been shown to compare favourably with standard cytotoxic chemotherapeutic drugs (Honn & Marnett, 1985) . However, even though it has been shown that PGAs enter into the cells and are transported to the nuclei (Fukushima et al., 1989) , their mechanism of action is not known. We have recently shown that PGA compounds potently inhibit the replication of human K562 erythroleukaemic cells (Santoro et al., 1986) and this action was not mediated by cAMP, in agreement with results previously reported in other systems (Hughes-Fulford et al., 1985) . In K562 cells PGA compounds did not directly alter DNA synthesis, but partially inhibited protein synthesis and glycosylation. PGA also induced the synthesis of a polypeptide of 74 kDa, which has now been identified as a heat shock protein (HSP) related to the major HSP70 group and which appears to be associated with inhibition of cell proliferation (Santoro et al., 1989) . The possibility that similar alterations in protein synthesis and maturation could be responsible for PGA-induced inhibition of FLC replication is under investigation. A better understanding of the mechanism by which prostaglandins inhibit cell proliferation could be useful in helping to design new drugs for cancer chemotherapy.
